Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,228 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Menopause, Postmenopausal Vaginal Atrophy
Interventions: estradiol, 10 mcg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 51
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 45 more

Conditions: Chronic Hepatitis C Virus Genotype 1
Interventions: BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more

Conditions: Breast Cancer Prevention
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 54 Years · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Hiv, Hormone Therapy
Interventions: Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Emtricitabine Tenofovir Alafenamide 200/25 mg; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 4
States / cities: Stanford, California • Iowa City, Iowa • Durham, North Carolina + 1 more

Conditions: Breast Cancer
Interventions: Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 27
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 23 more

Conditions: Covid19
Interventions: Famotidine 20 milligram tablet; Drug
Lead sponsor: drpykessupplements.com; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Fairfield, Connecticut

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK376501, Midazolam, Rosiglitazone, Flurbiprofen; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Mild Cognitive Impairment
Interventions: Project 2, Phase 2: Intelligent Adaptive System; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Tallahassee, Florida • Champaign, Illinois • New York, New York

Conditions: Interaction
Interventions: Diclofenac, curcumin; Drug · Dietary Supplement
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: HIV Infections
Interventions: Raltegravir poloxamer film coated tablet, Raltegravir chewable tablet, Raltegravir oral granules for suspension (20 mg/mL); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 29
States / cities: Alhambra, California • La Jolla, California • Los Angeles, California + 19 more

Conditions: HIV Infections
Interventions: Raltegravir and Maraviroc in combination; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Orlando, Florida • Henderson, Nevada + 3 more

Conditions: Advanced Solid Tumors
Interventions: ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 12
States / cities: Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more

Conditions: Vaping, Nicotine Dependence
Interventions: Double Blind Varenicline, Double Blind Placebo, QuitVaping, This Is Quitting; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 25 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hot Flashes
Interventions: Fezolinetant, placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 65
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Bioequivalence Study in Healthy Subjects, PK/PD
Interventions: 10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet; Drug
Lead sponsor: Sarfez Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Vienna, Virginia

Conditions: Melanoma
Interventions: Durvalumab, Dabrafenib, Trametinib; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 7
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 4 more

Conditions: PTSD
Interventions: TNX-102 SL; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 19 more

Conditions: Smoking Cessation
Interventions: Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8,144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 77
States / cities: Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more

Conditions: Borderline Personality Disorder
Interventions: BI 1358894, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Anaheim, California • Temecula, California • Upland, California + 13 more

Conditions: Solid Tumor
Interventions: Sirolimus, Cyclophosphamide, Etoposide, Celecoxib; Drug
Lead sponsor: Emory University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: Safety and Tolerability
Interventions: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days; Drug
Lead sponsor: MerLion Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cystic Fibrosis
Interventions: VX-661/Ivacaftor, Ivacaftor, Placebo matched to VX-661/ ivacaftor, Placebo matched to Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more

Search by objective public record fields.

Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2

Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

R5 Integrase Study in HIV-1 Naive Patients

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Varenicline for Nicotine Vaping Cessation in Adolescents

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation